Everest’s US$250 million buy signals rising global appetite for China biotech

Global investment in Chinese biotechnology companies is accelerating significantly, with major sovereign wealth funds from Singapore and Abu Dhabi joining domestic state-backed investors in record-breaking licensing agreements. The Everest acquisition valued at $250 million exemplifies this shift, demonstrating increased confidence in China's biotech sector innovation and commercial potential. This trend reflects broader changes in cross-border pharma partnerships and international capital flows toward emerging biotech hubs.